ScienceFresh
Stealth biotech Stipple bets on secretive ADCs
Stipple is focusing on developing antibody-drug conjugates (ADCs) to target cancer. The company's secretive approach aims to innovate in the biotech space with potentially groundbreaking therapies.
0 upvotes
What happened
Stipple is focusing on developing antibody-drug conjugates (ADCs) to target cancer.
Why it matters
The company's secretive approach aims to innovate in the biotech space with potentially groundbreaking therapies.